Mannitol osmotherapy

Osmotic agent that draws free water across intact endothelium into the intravascular space, then is filtered unchanged at the glomerulus where it generates an osmotic diuresis. Onset minutes; duration ~4–6 hr.

Open calculator →

Clinical background

Mannitol is the prototype osmotic agent in veterinary emergency and critical care. It is a six-carbon polyol that does not cross intact endothelium, is not metabolized, and is filtered freely at the glomerulus without significant tubular reabsorption. Those three properties make it useful across five distinct clinical indications, each with its own dose and timing per Plumb’s: osmotic diuresis (the only labeled indication, though not FDA-approved), oliguric acute kidney injury, acute glaucoma refractory to topical agents, increased intracranial pressure from cerebral edema, and adjunctive treatment of uroliths. The dosing differs enough between these indications that a single one-size-fits-all dose is unsafe, so the calculator front-loads the indication choice.

Mechanism

When mannitol enters the bloodstream, plasma osmolality rises by roughly the molar concentration of the dose. Water moves from interstitial and intracellular compartments into plasma along the osmotic gradient, expanding intravascular volume and reducing tissue water content. The drug is then cleared by glomerular filtration at near-passive rate; in the tubular lumen its presence as a non-reabsorbable solute prevents water reabsorption, producing the osmotic diuresis.

For cerebral edema, the benefit comes from the first part of that sequence: water exits the brain extracellular and (over a longer time course) intracellular compartments and enters plasma. ICP drops within minutes. The effect persists for 4–6 hours until renal clearance of mannitol resolves the gradient. The dose-response is roughly linear up to about 1 g/kg; beyond that, additional dose mostly increases the diuretic effect without further ICP benefit, while accumulation risks (see below) rise.

For oliguric AKI, the value is in the renal half of the mechanism. A patient with reduced glomerular filtration and a hypoperfused medulla benefits from a transient solute load that maintains tubular flow. If the patient responds (measurable urine output within 1–2 hours), the next steps are either to repeat the bolus or transition to a maintenance CRI. If there is no response, the kidney has lost the ability to handle the solute load, and further mannitol simply expands extracellular volume in a patient who cannot excrete it.

For glaucoma, the IV bolus produces a brisk plasma-osmotic gradient that pulls water from aqueous and vitreous humor across the ciliary body and retinal vasculature, dropping IOP within 30 minutes. The effect is dramatic and short-lived; it buys time for definitive treatment (topical agents, surgical decompression, or enucleation of a non-visual painful eye).

For uroliths, the combination of bolus loading and a sustained 1 mg/kg/min CRI maintains tubular flow and osmotic dilution of the urine, supporting medical dissolution protocols and reducing the chance of obstruction during stone passage or fragmentation.

Osmotic diuresis (label indication)

The only labeled indication in Plumb’s, though notably not FDA-approved for any veterinary species. Dose is 1.5–2 g/kg IV over 30 minutes. In practice, this is the indication least commonly invoked in small animal emergency medicine; the extra-label indications (especially cerebral edema and oliguric AKI) account for the majority of clinical use. Monitor urine output, serum electrolytes, and hydration; the obligate diuresis can drive hypokalemia and hyperchloremia in patients without concurrent maintenance fluids.

Increased intracranial pressure / cerebral edema

Traumatic brain injury, severe meningoencephalitis, intracranial mass with peritumoral edema, and the immediate post-arrest brain are the classic indications. The decision to give mannitol is clinical: signs of intracranial hypertension (deteriorating mentation, anisocoria, Cushing reflex with bradycardia and hypertension, posturing) in a patient with a plausible intracranial process. There is rarely time to wait for definitive imaging.

Plumb’s dose is 0.5–1 g/kg IV or intraosseously over 15–20 minutes. Repeat boluses every 6–8 hours may be given if needed. IV CRI is explicitly NOT recommended for this indication, because sustained mannitol exposure allows the drug to cross a disrupted blood-brain barrier; once inside the brain, it pulls water back across the new gradient, worsening edema. This is the reverse osmotic shift, and it is the reason continued mannitol dosing past 24–48 hours of refractory ICP is more often harmful than helpful.

Hypertonic saline is the main alternative and is preferred over mannitol in the hypovolemic patient: mannitol’s obligate diuresis will worsen volume status, while hypertonic saline expands volume as it lowers ICP. In the normovolemic to hypervolemic patient, mannitol has the advantage of removing some of that extra volume through its osmotic diuresis.

The most under-recognized failure mode is administering mannitol to a hypotensive patient. The transient plasma expansion from mannitol can mask hypovolemia for 30–60 minutes; once the diuretic effect kicks in, the patient becomes profoundly hypotensive, and cerebral perfusion pressure drops despite the lower ICP. Always confirm volume status and replace fluid losses concurrently. Hypotension after mannitol is a treatment-induced injury, not a treatment-resistant patient.

Oliguric acute kidney injury

This indication has narrowed over the past two decades as the limitations have become clearer, but mannitol still has a role as a diuretic-response test in the oliguric patient who is volume-replete (a key qualifier) but not producing urine. Plumb’s dose is 0.25–1 g/kg IV over 15–20 minutes. Urine output is measured before and 1–2 hours after the bolus.

A clear response (urine output ≥1 mL/kg/hr) confirms that the tubules are still functional. The next step is either to repeat the bolus every 4–6 hours OR to transition to a maintenance CRI at 60–120 mg/kg/hr. Total daily dose conventionally capped at 2 g/kg/day, both for the cumulative cerebral and renal toxicity concerns and because patients who need higher exposure usually need renal replacement therapy instead.

No response within 2 hours says the kidney has lost its ability to respond, and repeated dosing is contraindicated; the patient needs renal replacement therapy or aggressive management of the underlying cause. Continued mannitol in a kidney that cannot excrete it produces severe volume overload, pulmonary edema, and worsening tubular injury through osmotic nephrosis.

Furosemide is sometimes combined with mannitol in the response test, on the theory that loop diuresis complements osmotic diuresis; the evidence for additive benefit is weak but the combination is not contraindicated.

Acute glaucoma (IOP reduction)

Mannitol drops IOP within 30 minutes and peak effect occurs around 60 minutes after the dose. Plumb’s dose is 1–2 g/kg IV over 10–20 minutes (note the shorter infusion window than other indications). The duration of effect is 4–6 hours, after which IOP returns to baseline unless definitive treatment has been started.

Plumb’s specifically recommends limiting water intake for 1–4 hours post-dose to prolong the osmotic effect. The rationale: if the patient drinks freely after the dose, oral water intake will partially refill the intravascular and interstitial compartments along the same gradient that’s pulling water out of the vitreous and aqueous, blunting the IOP reduction.

This is typically a single-dose intervention. Topical agents (timolol, dorzolamide, latanoprost) and surgical or laser intervention are the definitive treatments; mannitol buys the time to organize those.

Adjunctive treatment of uroliths

Plumb’s protocol is 0.25–0.5 g/kg IV over 20 minutes as a loading dose, followed by a continuous infusion at 1 mg/kg/min (= 60 mg/kg/hr). The sustained osmotic diuresis maintains tubular flow and dilutes the urine, supporting medical dissolution protocols and reducing the chance of mechanical obstruction during stone passage or fragmentation.

Monitor urine output, hydration status, and serum electrolytes throughout the CRI. The sustained diuresis can drive hypokalemia and hyperchloremia; concurrent maintenance fluids with potassium supplementation are typical. The 2 g/kg/24h cumulative ceiling matters here: at 60 mg/kg/hr, 24 hours of infusion equals 1.44 g/kg, approaching but not exceeding the ceiling. Longer infusions should prompt a discussion of alternative management.

Cumulative-dose ceiling and paradoxical effects

Two distinct paradoxical effects emerge with sustained or high cumulative dosing.

In the brain, prolonged mannitol exposure allows it to cross the disrupted blood-brain barrier. Once inside the brain parenchyma, mannitol pulls water back across the new gradient, worsening cerebral edema. This is the reverse osmotic shift, and it is the reason Plumb’s explicitly does NOT recommend IV CRI for the cerebral edema indication.

In the kidney, accumulation of filtered mannitol in the proximal tubule produces a syndrome called osmotic nephrosis: cytoplasmic vacuolation of tubular epithelium, cell swelling, and tubular dysfunction. The clinical signature is rising creatinine and falling urine output despite continued mannitol infusion. It mimics or worsens existing AKI and is dose-dependent.

The conventional ceiling is 2 g/kg/24h, or sustained therapy beyond 5–7 days. Serum osmolality monitoring (target <320 mOsm/kg) provides an empirical safety check that supersedes the strict cumulative dose limit: if the patient is below 320, the cumulative number is less important than the trend.

Crystallization and the in-line filter

Mannitol crystallizes at room temperature and below. The crystals are mannitol, not contamination, but they are an embolic hazard if injected into the bloodstream. Standard practice has three parts:

First, warm the bag to body temperature before drawing. A warm-water bath, an in-cabinet warmer, or even body heat in a held bag will redissolve crystals over 5–10 minutes. Do NOT administer mannitol with visible crystals remaining after warming; redissolve first.

Second, administer through a 0.22 µm in-line filter. This is non-negotiable and catches micro-crystals that may form during slow infusion in a cool room.

Third, never freeze the bag. Freezing nucleates large crystal growth that does not redissolve cleanly.

A small percentage of clinical adverse events with mannitol trace to crystal embolism. The filter requirement eliminates the entire risk class.

Contraindications

Anuric AKI without diuretic response (any non-trivial mannitol dose worsens volume overload in a kidney that cannot excrete it).

Severe heart failure with volume overload (the transient plasma expansion will precipitate frank pulmonary edema before the diuresis catches up).

Intracranial hemorrhage with active bleeding (the osmotic gradient and the diuresis can worsen hematoma expansion; hypertonic saline has a more favorable hemodynamic profile in this setting).

Severe hyperosmolar states (existing osmolality >320 mOsm/kg). Additional osmolar load risks irreversible CNS injury.

Severe hypovolemia (give fluid first; mannitol’s obligate diuresis worsens volume status).

Monitoring

Serum sodium and osmolality every 6–12 hours during sustained therapy. Target osmolality 300–320 mOsm/kg; sustained values above 320 are the strongest signal to stop.

Urine output, hourly if possible. Falling output despite continued mannitol is the sign of osmotic nephrosis or unresolved underlying pathology.

Mentation and neurologic exam (for the cerebral edema indication). Rebound worsening 30–60 minutes after a dose suggests reverse osmotic shift; consider transitioning to hypertonic saline or definitive intervention.

Cardiovascular status. Hypotension after mannitol is treatment-induced and reflects unmasked hypovolemia; replace fluid before the next dose.

Notes on stock concentration

20% mannitol (200 mg/mL = 0.20 g/mL) is the most common US veterinary stock concentration. 25% (250 mg/mL) is used in some hospitals where 20% is unavailable. Both crystallize at room temperature; the higher concentration crystallizes more readily and is more dependent on warming and in-line filtration. Compounded mannitol is not appropriate; commercial preparations are the standard of care.

The calculator defaults to 20% because it is more widely stocked, the dilution math is mentally easier (0.5 g/kg in a 20 kg dog = 10 g = 50 mL of 20%), and the lower viscosity is gentler on small peripheral catheters.